Company exits low-margin product lines, invests in higher-margin, innovative CEA-informed, better-for-you shelf-stable products, and expands global reach Conference Call to Be Held Today at 8:00 am ET. BELVIDERE, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, better-for-you, sustainable produce and products, today reported strong core business performance for the three months ended June 30, 2025, and shared a strategic business update. This performance reflects the Company’s disciplined portfolio optimization strategy following a recent acquisition, which involved eliminating underperforming, low-margin product lines and making targeted investments in higher-margin, innovative,...

NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) — CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today its financial results for the quarter ended June 30, 2025. Financial Highlights for the three months ended June 30, 2025 Total revenues in the three-month period ended June 30, 2025, was $17.6 million compared to $13.8 million in the comparable period in 2024. In the following table, revenue is disaggregated by type of revenue for the three months ended June 30, 2025 and 2024:    Three Months Ended    June 30,(in thousands)   2025 2024License   $ − $ −Professional services     9,381   6,973Processing and maintenance     6,564   5,694Third party     1,649   1,130Total   $ 17,594 $ 13,797Income...

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q2 2025. Management Commentary: “Q2 marked another milestone in Avicanna’s journey, fueled by advancements in our pipeline and deeper engagement with the Canadian medical community. In Canada, we delivered growth across multiple commercial channels, underscoring the strength of our proprietary, high-margin portfolio. Achieving positive adjusted EBITDA for the first half of 2025 reflects the financial discipline and operational focus that continue to drive our performance. These results reinforce our ability to execute our strategy...

Second quarter 2025 GAAP net loss of $(13.2) million or $(0.60) per basic weighted average common share and  Distributable Earnings(1) of $3.4 million or $0.15 per basic weighted average common share Announces Intention to Convert from Mortgage REIT to BDC WEST PALM BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — Advanced Flower Capital Inc. (Nasdaq: AFCG) (“Advanced Flower Capital”, “AFC” or the “Company”) today announced its results for the quarter ended June 30, 2025. AFC reported generally accepted accounting principles (“GAAP”) net loss of $(13.2) million or $(0.60) per basic weighted average common share and Distributable Earnings of $3.4 million or $0.15 per basic weighted average common share for the second quarter of 2025. “During the quarter, we focused on working through our non-accrual credits with the goal to achieve...

–        Revenue of $5.2 million–        Gross margin of 33%–        Adjusted EBITDA margin of 3%–        Awarded three new projects HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) — Koil Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, released today its second quarter 2025 results and announced three new projects. “After a modest first half of 2025, momentum is building. Today, we announced three new projects, and recent weeks have brought a sharp rise in service activity and robust order intake on fixed‑price contracts,” said Erik Wiik, President and Chief Executive Officer of KOIL Energy. “These are clear indicators of strengthening demand heading into the second half of the year.” Second Quarter 2025 Results: For the three months ending...

Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy On track with plans to nominate first development candidates for wholly owned masked T cell engager programs in second half of 2025 $121.6 million in cash and cash equivalents as of June 30, 2025, with anticipated cash runway through end of third quarter of 2026 WALTHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the second...

Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 2024 50% Growth in Revenue for International Medical Cannabis International Medical sales now 57% of Total Revenue Cash Balance of $10.4 Million at the end of Q2, Increased from $8.4 Million in Q1 2025 Management to Host Conference Call / Webcast on August 14th, 2025 at 10:00 am ETTORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and six months ended June 30, 2025. MediPharm achieved strong year-over-year revenue growth in Q2 2025 and continued to advance its international medical cannabis strategy, supported by a...

– Definitive asset purchase agreement for 11 MW Bitcoin mining site in Mississippi– Direct mining margin improved to 41.0% from 38.5% in Q1 2025– $0.1 million GAAP net income and $2.6M Core EBITDA, up from sequential $5.4 million net loss and $2.8 million negative Core EBITDA in Q1 2025, respectively– Held 150.4 Bitcoin on July 31, 2025 valued at approximately $18.0 million, as of August 11, 2025 TAMPA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin mining and technology-based specialty finance company, today reported financial results for the three months ended June 30, 2025. Q2’25 Financial HighlightsTotal revenue for the quarter was $1.9 million dollars, down 18.7% sequentially from Q1 2025 and down 36.0% year-over-year. The...

Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric Cancer Department of Defense STTR Grant to advance INKTs in GVHD announced; program advancing New clinical grant awarded to launch AgenT-797 in GvHD clinical trial; target initiation 2H2025NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced financial results for the second quarter ended June 30, 2025, and provided a business update highlighting major clinical achievements, a strengthened balance sheet, and expanded funding to advance both oncology and immunology programs. “In Q2, we demonstrated the power of our platform with high impact clinical results, publication...

Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia LX2006 selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access Eight participants dosed in Phase I/II clinical trial (HEROIC-PKP2) of LX2020 for PKP2-ACM; interim clinical data update on track for second half of 2025 Strategic partnership announced with Perceptive Xontogeny Venture Funds and venBio Partners to advance non-viral, RNA-based therapeutics for genetic cardiac diseases $80 million equity financing to support development of clinical stage pipeline; cash, cash equivalents and investments in marketable...